(Q42982601)

12 November 2017

title

Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads (English)

1 reference

12 November 2017

1 reference

1 reference

1 reference

1 reference

1 reference

13

Hiromitsu Kumada

1 reference

12 November 2017

2

Fumitaka Suzuki

1 reference

12 November 2017

11

Kenji Ikeda

1 reference

12 November 2017

7

Masahiro Kobayashi

1 reference

12 November 2017

8

Yoshiyuki Suzuki

1 reference

12 November 2017

6

Norio Akuta

1 reference

12 November 2017

10

Yasuji Arase

1 reference

12 November 2017

1

Hitomi Sezaki

1 reference

12 November 2017

9

Satoshi Saitoh

1 reference

12 November 2017

3

Yusuke Kawamura

1 reference

12 November 2017

5

Tetsuya Hosaka

1 reference

12 November 2017

Hiromi Yatsuji

4

1 reference

12 November 2017

Yuzo Miyakawa

series ordinal

12

1 reference

12 November 2017

publication date

28 October 2008

1 reference

Digestive Diseases and Sciences

12 November 2017

published in

1 reference

12 November 2017

volume

54

1 reference

12 November 2017

issue

6

1 reference

12 November 2017

page(s)

1317-1324

1 reference

https://scigraph.springernature.com/pub.10.1007/s10620-008-0500-y

12 November 2017

exact match

0 references

cites work

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10620-008-0500-Y

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10620-008-0500-Y

Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10620-008-0500-Y

Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening

21 January 2018

1 reference

12 December 2020

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

12 December 2020

1 reference

12 December 2020

The scientific challenge of hepatitis C.

1 reference

12 December 2020

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

12 December 2020

Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1.

1 reference

12 December 2020

Characterization of estrogen receptor from human liver

1 reference

12 December 2020

Natural history of hepatitis C.

1 reference

12 December 2020

Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats

1 reference

12 December 2020

Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C

1 reference

12 December 2020

Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response.

1 reference

12 December 2020

Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation

1 reference

12 December 2020

Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: Not just a cholestatic problem

1 reference

12 December 2020

Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan

1 reference

12 December 2020

Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.

1 reference

12 December 2020

Chronic hepatitis C is mild in menstruating women

1 reference

12 December 2020

1 reference

12 December 2020

Genotype and viral load as prognostic indicators in the treatment of hepatitis C.

1 reference

12 December 2020

Natural history of chronic hepatitis C

1 reference

12 December 2020

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

12 December 2020

Expression of type I and type III collagens during the course of dimethylnitrosamine-induced hepatic fibrosis in rats

1 reference

12 December 2020

Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study

1 reference

12 December 2020

Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome

1 reference

12 December 2020

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

12 December 2020

Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. The Hepatitis/HIV Spanish Study Group.

1 reference

12 December 2020

Assessment of fibrosis progression in untreated irish women with chronic hepatitis C contracted from immunoglobulin anti-D.

1 reference

12 December 2020

Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen.

1 reference

12 December 2020

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

1 reference

12 December 2020

Evaluation of long-term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral load.

1 reference

12 December 2020

Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong

1 reference

12 December 2020

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

1 reference

12 December 2020

Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection

1 reference

12 December 2020

Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure.

1 reference

12 December 2020

Hepatitis C virus genotypes and quantitation of serum hepatitis C virus RNA in liver transplant recipients: relationship with severity of histological recurrence and implications in the pathogenesis of HCV infection

1 reference

12 December 2020

Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection

1 reference

12 December 2020

Hepatitis C in injecting drug-using women during and after pregnancy

1 reference

12 December 2020

10.1007/S10620-008-0500-Y

Identifiers

DOI

1 reference

12 November 2017

1 reference